Parenteral grade, vegetable-derived Cholesterol (FDA DMF 29599)
7 September 2016 | By Wilshire Technologies
The virtues of vegetal- vs. animal-derived actives and excipients are well-known and need no elaboration...
List view / Grid view
News
NICE says Roche’s skin cancer drug not cost effective
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year...
Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The combination of Galenica's Vifor Pharma business with Relypsa will create a significant player in cardio-renal care in the US and further strength...
Asian licensing deals for Ergomed and Aeterna Zentaris’ endometrial cancer drug
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial...
Gelesis appoints new Chief Operating Officer in anticipation of obesity product launch
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer...
EU funds stem cell technologies for heart repair – Eppendorf is project partner
5 September 2016 | By Eppendorf
Within the EU Research and Innovation program Horizon 2020 the European Union is now funding the TECHNOBEAT research project with almost 6 million Euro...
Eisai bewildered as IQWIG fails to recognise OS benefit of liposarcoma drug
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in…
Predosing NHL patients with lilotomab before betalutin therapy lowers haematological toxicity
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective...
How to get the best out of your high pressure homogeniser
5 September 2016 | By Biopharma Group
Fluid processing requirements are becoming ever more stringent, and so high pressure homogenisation is increasingly surfacing as a solution to meeting these needs...
Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two…
Novo Nordisk’s insulin pen receives EU expanded use approval to treat more patients with type 2 diabetes
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control...
Aesica Pharmaceuticals implements Ci-DMS Weigh and Dispense from CI Precision
2 September 2016 | By CI Precision
Aesica Pharmaceuticals is implementing CI Precision’s MES solution (Ci-DMS) in their dispensing areas to remove labour-intensive manual processes, improve data integrity and integrate with their SAP ERP system.
NICE recommends Bayer’s prostate cancer drug for routine NHS use
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer...
PerkinElmer launches ChemDraw® cloud platform at 2016 ACS Fall National Meeting & Exposition
2 September 2016 | By PerkinElmer Inc
ChemDraw software moves to the cloud for enhanced collaboration among chemists and biologists...
Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…
